Long-term management of acquired thrombotic thrombocytopenic purpura using serial plasma ADAMTS13 measurements

European Journal of Haematology

Volumn 88, Issue 6, 2012, Pages 518-525

  Knovich, Mary Ann ^a   Farland, Andrew ^a   Owen, John ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ADAM proteins; ADAMTS13; Immunosuppression; Long term treatment of TTP; Plasmapheresis; Refractory TTP; Rituximab; Thrombotic thrombocytopenic purpura; TTP relapse

Indexed keywords

PREDNISONE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; ENZYME ACTIVITY; ENZYME REPLACEMENT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MAINTENANCE THERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; PLASMAPHERESIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE;

EID: 84861188810     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01767.x     Document Type: Article

References (30)

1. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87:4223-34.
2. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-94.
3. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
4. Raife TJ. ADAMTS13 and thrombotic thrombocytopenic purpura: where we are and where we need to go. Transfusion 2010;50:1640-2.
5. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-9.
6. Franchini M, Mannucci PM. Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. Blood Transfus 2008;3:127-35.
7. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008;112:11-8.
8. Sarode R. Atypical presentations of thrombotic thrombocytopenic purpura: a review. J Clin Apher 2009;24:47-52.
9. Knovich MA, Lawson HL, Burke MH, McCoy TP, Owen J. Rapid quantitative assay of ADAMTS13 activity on an automated coagulation analyzer: clinical applications and comparison with immunoblot method. Am J Hematol 2008;83:654-6.
10. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005;129:93-100.
11. Cleveland WS. The Elements of Graphing Data. Pacific Grove, California: Wadsworth & Brooks/Cole, 1985.
12. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-8.
13. Cataland SR, Yang SB, Witkoff L, Kraut EH, Lin S, George JN, Wu HM. Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol 2009;83:559-64.
14. Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, Wu HM. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008;141:651-8.
15. Johnson KK, Terrell DR, Lammle B, Hovinga JK, George JN, Vesely SK. Predicting risk for relapse in patients who have recovered from thrombotic thrombocytopenic purpura (TTP). Blood 2006;108:91.
16. Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol 2000;65:251-5.
17. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood 2007;109:2815-22.
18. Doldan-Silvero A, Cevedo-Gadea C, Habib C, Freeman J, Johari V. ADAMTS13 activity and inhibitor. Am J Hematol 2008;83:811-4.
19. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS 13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005;106:1932-7.
20. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008;93:232-9.
21. Elliott MA, Heit JA, Pruthi RK, Gastineau DA, Winters JL, Hook CC. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 2009;83:365-72.
22. Knobl P, Haas M, Laczika K, Varadi K, Turecek PL. Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13. J Thromb Haemost 2003;1:187-9.
23. Cataland SR, Jin M, Lin S, Kraut EH, George JN, Wu HM. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol 2008;83:911-5.
24. Nosari A, Redaelli R, Caimi TM, Mostarda G, Morra E. Cyclosporine therapy in refractory/relapsed patients with thrombotic thrombocytopenic purpura. Am J Hematol 2009;84:313-4.
25. Nosari A, Bernuzzi P, Corneo R, Pungolino E, Muti G, Rossi V, Morra E. Late response to cyclosporine in refractory thrombotic thrombocytopenic purpura. Int J Hematol 2002;76:284-6.
26. Feys HB, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010;116:2005-10.
27. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002;100:710-3.
28. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:1156-64.
29. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010;47:187-98.
30. Arbuthnot J. Of the laws of chance, or, A method of calculation of the hazards of game plainly demonstrated and applied to games at present most in use: which may be easily extended to the most intricate cases of chance imaginable. London: Printed by Benj. Motte, and sold by Randall Taylor, 1692.